CD19 and acute lymphoblastic leukemia: RNA-sequencing identified a CD19 splice variant as a biomarker of the failure of blinatumomab (anti-CD19/CD3) therapy in B-cell progenitor ALL [48], and a USP7 gene signature was associated with resistance to therapy in AML patients [49].